Kornimate/medical-research-clean huggingface dataset:
intravenous dexamethasone for ropivacaine axillary block

Conditions: Postoperative Pain; Anesthesia; Forearm Injuries

Summary: prospective monocentric double-blind controlled randomised trial aim is to assess prolonged postsurgical analgesia by intravenous dexamethasone versus intravenous placebo, after ultrasound guided axillary brachial plexus block


Eligibility criteria:
inclusion criteria: * asa 1,2 et 3 * surgery under axillary brachial plexus block * aged \>18 years * signed information consent exclusion criteria: * impaired coagulation * contraindication to regional anesthesia or technical impossibility * opioids or pain killers abuse or addiction * steroids consumption in the past 6 months * dementia or under administrative supervision * delay of surgery to short to allow regional anesthesia * pregnancy and breastfeeding * allergy and contraindication to dexamethasone or ropivacaine * anticipated bad observation of treatment * patient enrolled in another trial

Keywords: anaesthetic techniques regional anesthesia brachial plexus block local anesthetic ropivacaine analgesia steroid dexamethasone placebo adjuvant ultrasound guided
phenotype correlates genotype of inherited retina dystrophies, retinitis pigmentosa, con>rod dystrophies.

Conditions: Retinitis Pigmentosa; Cone Dystrophy; Usher Syndromes; Retina; Dystrophy

Summary: patients with retina dystrophies (retinitis pigmentosa, cone\>rods dystrophies, usher and syndromic) will be correlated with genotype and validate inheritance mode by segregation analysis.

patients with retina dystrophies (retinitis pigmentosa, cone\>rods dystrophies, usher and syndromic, etc.) will be correlated with genotype and validate inheritance mode by segregation analysis. ocular exam of proband, parents and two unaffected siblings is needed, retina analysis, autofluorescence and ocular coherence tomography (oct) are needed as well as family map. blood samples 10ml max blood extraction will be sent and genotype will be analyzed.

Eligibility criteria:
inclusion criteria: 1. diagnosis of inherited retina dystrophy or retinitis pigmentosa 2. must be able to perform all study tests. 3. must be able to visit every year. exclusion criteria: 1) not willing to visit every year.
withholding of life-sustaining treatment and quality of life after severe acute brain injury: qualitative analysis and ethical issues

Conditions: Quality of Life; Brain Injuries; Post ICU

Summary: withdrawal of life-sustaining treatment affects 10-15% of icu patients, including those with severe acute brain injury, whose care appears futile in terms of prognosis based on clinical and paraclinical data, expected quality of life, patient preferences, age, or reduced quality of life. there are few studies on withholding treatment compared with withdrawing treatment, and even fewer on survivors after a decision to withhold treatment. quality of life is defined by who as "an individual's perception of his or her position in life in the context of the culture and value systems in which he or she lives and in relation to his or her goals, expectations, standards and concerns". the relationship between quality of life and neurological outcome after severe acute brain injury is controversial and therefore difficult to predict. that's why the investigators question the legitimacy of making decisions to withhold treatment from patients with severe acute brain injury based on their expected quality of life, when this prediction is uncertain.


Eligibility criteria:
inclusion criteria: patients: * with severe acute brain injury (tbi, stroke, central nervous system infection). * admitted in the neurocritical care unit in 2022. * followed up 24 months after icu between 15th april 2024 and 31st august 2024. exclusion criteria: patients: * death in 2024, * refusal by patient or relative.

Keywords: quality of life withholding of life-sustaining treatments withdrawal of life-sustaining treatment severe acute brain injury
effects of intravascular laser irradiation of blood for mitochondral dysfunction in cerebral ischemic stroke

Conditions: Ischemic Stroke

Summary: background : this research is designed through randomization, control, and double-blind trial to explore the clinical effectiveness of intravenous laser irradiation of blood for ischemic stroke patient; the research will further explore the changes of mitochondria function after treatment. the light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes. pain control is indicated in such treatment, but still lacking evidence of neurological symptoms and functional improvement. purpose:this research is designed through randomization, control, and double-blind trial to therapeutic effect and platelet activity after intravenous laser irradiation of blood for ischemic stroke patient. furthermore, to establish a new way of clinical therapy. method: the investigators plan to recruit 20 patients who are between the ages of 20 to 80 years old. the participants are required to have clear conscious and be able to communicate. the patient with mild to moderate stroke ( nihss=1-15), which onset between one month to 2 years will be included. the treatment group will receive an intravenous helium-neon laser phototherapy. a vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. the power is set between 5mw, 30 minutes each time, once everyother day for 3 days each week, for 2 weeks (total 6 times in one course). the steps for the control group are the same, except that the output power is adjusted to zero intensity. this plan will be explained to the patient in detail during the outpatient visit and patients will sign the consent form upon agreement. before intravenous laser irradiation,three days, one month, and three months after the therapy, 20 ml of autologous peripheralvenous blood need to be drawn for basic blood tests and platelet activity tests. at the same time, the clinical functions of patients will be evaluated, including nihss, mrs.


Eligibility criteria:
inclusion criteria: * aged between 20 to 80 years old * able to speak and understand mandarin/taiwanese * no cognitive impairment * residual motor function impairment (mrs\>1) * mild stroke (nihss=1-4) or moderate stroke(nihss=5-15) * no psychological disease exclusion criteria: * severe stroke (nihss=16-42) * history of intracerebral hemorrhage and other major surgery * history of malignancy, chronic kidney disease * active infection * chronic hepatitis b or chronic hepatitis c * unstable angina or acute myocardial infarction within 6 months * severe cognition impairment * pregnancy

Keywords: ischemic stroke intravenous laser irradiation of blood mitochondria activity
study to assess the impact of hepatic impairment on the safety, tolerability and pharmacokinetics of single-dose 200 mg of pf-868554

Conditions: HEPATITIS C (HCV)

Summary: the metabolism of pf-00868554 is primarily mediated by cyp3a, and it is anticipated that hepatic impairment will modify pf-00868554 plasma concentrations. hence, it is important to determine the impact of varying degrees of hepatic impairment on the pharmacokinetics, safety and toleration of 200 mg pf-00868554 administered as a single-dose.


Eligibility criteria:
inclusion criteria: * male or females subjects of non-childbearing potential between the ages of 18 and 62 years of age, inclusive; * body mass index (bmi) of approximately 18 to 35 kg/m2; and a total body weigh \>50 kg (110 lbs); exclusion criteria: * subjects with class c classification (severe - child-pugh scores greater than 10); * severe ascites and/or pleural effusion; * had a transplanted kidney, heart or liver;
study to evaluate the efficacy and safety of oral difelikefalin (cr845) for moderate to severe pruritus in subjects with atopic dermatitis

Conditions: Pruritus; Atopic Dermatitis

Summary: this is a multicenter, randomized, double-blind, 4-arm, placebo-controlled study to evaluate the efficacy and safety of twice-daily (bid) oral difelikefalin (cr845) in adult subjects with atopic dermatitis (ad) and moderate to severe pruritus.

the study will consist of a 30-day screening period, a 7-day run-in period, a 12-week placebo-controlled treatment period followed by a 4-week active extension period and a follow up visit approximately 7 days after the last dose of study drug. all subjects will sign an informed consent form (icf) and undergo screening for study eligibility. subjects will be randomized to receive either placebo or difelikefalin (cr845) tablets at a dose of 0.25 mg, 0.5 mg, or 1.0 mg, orally bid. intake of the first dose of study drug will be at day 1. subjects who complete the placebo-controlled treatment period of the study will transition into the active extension upon completion of the week 12 visit assessments. all subjects in the active extension will receive difelikefalin (cr845).

Eligibility criteria:
key inclusion criteria: to be eligible for inclusion into the study, a patient must meet the following criteria: * subject has clinically confirmed diagnosis of active ad; * subject has at least a 12-month history of ad; * subject has chronic itch related to ad; * subject has moderate to severe pruritus; * female subject is not pregnant or nursing during any period of the study. key exclusion criteria: a patient will be excluded from the study if any of the following criteria are met: * subject has clinically infected ad; * subject has pruritus attributed to a cause other than ad; * subject has any clinically significant medical condition or physical/laboratory/ecg/vital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.

Keywords: atopic dermatitis pruritus cr845 chronic itch difelikefalin itch itching generalized pruritus eczema
a novel, low-cost, handheld 3d imaging system for improved screening for cervical neoplasia in resource-limited settings

Conditions: Cervical Intraepithelial Neoplasia

Summary: the purpose of this study is to evaluate the design and engineering of a new minimally invasive medical imaging device (cervimage™). investigators are trying to find out if cervimage™ is reliable and easy to use to obtain clinical 3d photographs and to record 3d measurements in human cervixes. investigators then plan to use these images to determine if cervimage™ design and engineering improvements need to be made.

this study intends to evaluate the design and engineering of an innovative, minimally invasive, 3d, and medical imaging device (cervimage™) for detecting cervical lesions. the research procedure and evaluation will be incorporated into the scheduled annual pap smear exam or colposcopic gynecologic exam that involves using a vaginal speculum. the cervimage™ camera will be positioned within the speculum approximately 1-2 cm distal to the cervix. it will not come into physical contact with the participant. data collection with the cervimage tm imaging device is expected to take less than 5 minutes. the study will generate live cervical images and gather qualitative feedback from both clinicians and participants. cervimage™ is not a diagnostic product, and this study will not be generating any efficacy or imaging data to be used for diagnostic or therapeutic purposes. if any abnormalities are observed in the cervimage™ procedure described, they will be further evaluated by the principal investigator. this will take place during the participant's routine gynecologic exam with colposcopy included as part of their scheduled clinical visit. the device will not be used for diagnostic purposes or for making any clinical decisions or recommendations.

Eligibility criteria:
inclusion criteria: * patient 21 to 70 years of age at screening * patients with known hpv infection or cervical intraepithelial neoplasia (16 patients) * healthy patients without history of hpv/cin (2 patients) * participants able to consent for themselves exclusion criteria: * cognitive impairment * currently pregnant * incarcerated individual * any condition which in the clinical judgement of the pi makes the subject unsuitable or unsafe for study enrollment

Keywords: cervical lesion intraepithelial dysplasia human papillomavirus (hpv) cervimage
a study of the experimental drug bkm120 with paclitaxel in patients with her2 negative, locally advanced or metastatic breast cancer, with or without pi3k activation

Conditions: Breast Cancer

Summary: this study evaluated whether the addition of daily bkm120 to weekly paclitaxel was effective and safe in treating patients with her2- locally advanced or metastatic breast cancer.

based on the efficacy results at the time of the interim analyses, the dmc recommended stopping the study at phase ii during the interim as it met the protocol pre-specified futility criteria. consequently, the phase iii portion of the study was not conducted.

Eligibility criteria:
inclusion criteria: * breast cancer that is locally advanced or metastatic * her2 negative disease, and a known hormone receptor status - er/pgr (common breast cancer classification tests) * a tumor sample must be shipped to a central lab for identification of biomarkers (pi3k activation status) before randomization * adequate bone marrow and organ function * measurable or non-measurable disease exclusion criteria: * prior chemotherapy for locally advanced or metastatic disease * previous treatment with pi3k or akt inhibitors * patient has symptomatic cns metastases * concurrent malignancy or malignancy within 3 years of study enrollment * hematopoietic colony-stimulating growth factors or radiation within 2-4 weeks prior to starting study drug * increasing or chronic treatment (\> 5 days) with corticosteroids or another immunosuppressive agent * active heart (cardiac) disease as defined in the protocol * known hypersensitivity or contraindications to use paclitaxel * pregnant or nursing (lactating) woman * certain scores on an anxiety and depression mood questionaire given at screening * other protocol defined criteria may apply

Keywords: bkm120 paclitaxel breast cancer metastatic locally advanced pi3k pik3ca pten
respiratory muscles and inspiratory muscle training

Conditions: Respiratory Muscles; Breathing Exercises

Summary: the effects of inspiratory muscle training (imt) remain controversial. many studies have examined the effect imt has on exercise performance, but any changes to the body that come from imt have yet to be looked at. this study will look at how someone breathes can change after imt. understanding how imt changes the body can help us use imt in different treatments.


Eligibility criteria:
inclusion criteria: * recreationally active, 'moderate' or 'high' category on international physical activity questionnaire short form questionnaire * able to read and understand english * pulmonary function within normal limits exclusion criteria: * history of or currently smoking * history or current symptoms of cardiopulmonary disease (including asthma and exercise induced asthma) * currently participating and training in a sport at a provincial, national, or international level * ulcer or tumor in the esophagus, a nasal septum deviation, or recent nasopharyngeal surgery * allergies to latex or local anesthetic * contraindications to exercise testing

Keywords: exercise
(18)f-fdg pet database of adult healthy individuals

Conditions: Healthy

Summary: epilepsy is the most common chronic neurological disorder in the world, affecting more than 50 million people worldwide. approximately 35% of patients with epilepsy are refractory to all available antiepileptic drugs. focal hypometabolism on interictal \[18f\]-fdg pet is a hallmark of the seizure onset zone as well as surrounding areas. using \[18f\]-fdg pet is thus particularly useful to determine the seizure onset zone of epileptic patients and thus to guide surgical treatment when antiepileptic drugs fail. interpretation of pet images primarily relies on standard visual analysis, but statistical analysis, with the widely used statistical parametric mapping (spm) software improves the diagnostic yield of pet. over the past years, some authors have thus reported that the use of spm can result in greater sensitivity and specificity of pet imaging in patients with partial epilepsy. in order to perform statistical analysis of pet images to compare brain metabolism of epileptic patients and healthy controls, it is necessary to collect a normative database of \[18f\]-fdg pet images in healthy controls. the purpose of this study is (i) collect a normative database of \[18f\]-fdg pet images in healthy adults controls to evaluate rigorously the diagnostic value of multimodal imaging for non-invasive localization of the ez and (ii) to evaluate the test-retest reliability of \[18f\]-fdg pet scanning.


Eligibility criteria:
inclusion criteria: * healthy adult controls * age 20-65 years * signed informed consent form. exclusion criteria: * contraindication to the mri * known neurological disease * adult subject to legal protection measure. * women of childbearing age who do not have effective contraception
clinical trial in patients with metastatic colorectal cancer

Conditions: Colon Cancer; Rectal Cancer

Summary: the objectives of this trial are to determine if cofactor in combination with 5-fu are effective in the treatment of metastatic colorectal cancer and to determine the side effects observed with the administration of cofactor and 5-fu.


Eligibility criteria:
inclusion criteria: * patients must have surgically incurable colon or rectal adenocarcinoma * karnofsky performance status of 60% or greater * patients may have symptomatic neuropathy * patients must have a life expectancy of at least 4 months * patients must be alimenting, receiving at least 1500kcal/day nutrition, by any route * patients must have bidimensional measurable disease for response assessment * patients may have received adjuvant chemotherapy with fluoropyrimidine therapy * patients must have recovered from the toxicities of prior therapy, at least 4 weeks since prior adjuvant chemotherapy and major surgery * serum creatinine less than 2.4mg%, serum bilirubin less than 3.0mg%, wbc greater than 3,200/mm2, agc greater than 1,500/mm3, platelet count greater than 90,000/mm3 and sgot (ast) and sgpt (alt) less than 3 times the upper limit of normal * male and non-pregnant, non-lactating female patients must be \>18 years old. exclusion criteria: * concurrent infection * failure of the patient or the patient's legal representative to sign the informed consent * inability to obtain informed consent because of psychiatric or complex medical problem * patients with unstable oncologic emergency * patients with unstable medical conditions such as angina, transient ischemic attacks, rising creatinine, accelerated hypertension, etc. * cerebellar neurologic syndromes such as parkinson's disease, multiple sclerosis and amyotonia * known intolerance to fluoropyrimidine therapy suggestive of dihydropyrimidine dehydrogenase deficiency.
effect of peep on arterial oxygen partial pressure in elderly patients with lithotomy position using lma supreme™

Conditions: Urinary Bladder Neoplasms; Prostatic Neoplasms

Summary: the purpose of the present study is to compare the effect of peep on arterial oxygen partial pressure in elderly patients undergoing urologic surgery using lma supreme™ in a lithotomy position.

positive end-expiratory pressure (peep) during general anesthesia with mechanical ventilation is routinely used as a standard lung protective strategy to prevent postoperative pulmonary complications including atelectasis. in urologic surgery, elderly patients are common. since aging decreases the elasticity of lung tissues and allowing the collapse of small airways, old age is a risk factor for postoperative atelectasis. lithotomy position is the preferred position in urologic surgery. however, it causes the abdominal viscera to displace the diaphragm cephalad, reducing lung compliance and resulting atelectasis. therefore, in elderly patients undergoing urologic surgery with lithotomy position, peep may be essential to prevent postoperative atelectasis. laryngeal mask airway (lma) has been widely used in urologic surgery with lithotomy position because of short surgical time and no necessity of administration of muscle relaxant. however, application of peep when using lma is still controversy. therefore, in the present study, we aimed to compare the effect of peep on arterial oxygen partial pressure in elderly patients undergoing urologic surgery using lma supreme™ in a lithotomy position.

Eligibility criteria:
inclusion criteria: * patients undergoing urologic surgery with lithotomy position under general anesthesia * elderly patients (65 ≤ age \< 80) * american society of anesthesiologists (asa) physical status: 1-3 * patients who voluntarily agreed to participate in this clinical study exclusion criteria: * heart failure (ejection fraction ≤ 40%) * hemodynamic instability during perioperative period * lung diseases (chronic obstructive pulmonary disease, asthma, bullae, pleural effusion) * obesity (bmi ≥ 30 kg/m2) * neck or upper respiratory tract pathologies * an increased risk of pulmonary aspiration * anticipation of the difficult laryngeal mask fixation due to poor dentition

Keywords: elderly lithotomy position peep laryngeal mask airway
morbidity, mortality and risk factors of mpox in hiv negative high risk sexual health clinic attenders and people living with hiv

Conditions: Monkeypox; HIV Coinfection

Summary: this data collection study aims to describe and compare the outcomes of mpox on people living with hiv (plhiv) and hiv-negative individuals who are on pre-exposure prophylaxis (prep). the study also aims to identify risk factors for specific mpox outcomes.


Eligibility criteria:
inclusion criteria: * diagnosis of mpx was more than 90 days prior to data collection * confirmed mpx infection by documented pcr testing of lesions between 1st may 2022 to 1st december 2023 * at least 18 years of age * cases (plwhiv + mpx) i) documented hiv-1 infection * cases (prep users + mpx) i) attended a clinic to receive prep exclusion criteria: * mpx diagnosed based on clinical criteria only * mpx diagnosis was within the last 90 days
uncovering a novel therapeutic target to reduce dementia risk in parkinson's disease

Conditions: Parkinson Disease; Mild Cognitive Impairment; Memory Impairment

Summary: the present study is a proof-of-concept clinical trial to test the efficacy of low doses of a repurposed anti-epileptic drug (levetiracetam) in treating memory problems in parkinson's disease (pd). neuroimaging techniques will be used to determine the effect of the drug on specific brain regions (hippocampal subfields). finally, baseline brain activity of pd patients with memory problems will be compared to pd patients without memory problems and healthy older adults to determine if activity in specific brain regions (hippocampal subfields) can be used to predict memory problems in pd. this information will be useful for future clinical trials to target drugs to these brain regions.


Eligibility criteria:
inclusion criteria: * parkinson's disease patients with amnestic mild cognitive impairment * parkinson's disease patients with no memory impairment * healthy volunteers * all participants must be eligible to take mri scans exclusion criteria: * dementia * contraindication to having mri * bipolar disorder, schizophrenia, alcohol or substance abuse * major depression * suicidal ideation * difficulty complying with protocol requirements * significant non-pd neurological disease * vascular dementia * sensitivity to levetiracetam * use of anticonvulsant medications * use of other excluded medications * severe renal impairment * clinically significant abnormalities in b12 or thyroid function test (below normative range for elderly) * females of childbearing potential